Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

An elderly patient receives a dose of the Pfizer COVID-19 vaccine at a clinic at Orange Farm, near Johannesburg, on June 3, 2021.

Denis Farrell/The Associated Press

The Toronto-based Mastercard Foundation says it will spend US$1.3-billion to revive the faltering vaccine effort in Africa, saying there is a “moral imperative” to respond to the mounting inequities that have left poorer countries slipping far behind the rich.

The foundation, Canada’s biggest charity with more than US$39-billion in assets, says it is making the donation to acquire COVID-19 vaccines for 50 million Africans and to take other steps to tackle the growing vaccine crisis in Africa.

Less than 2 per cent of Africans have received any vaccine so far, while a growing number of wealthy countries – including Canada – have provided at least one dose to more than half of their populations.

Story continues below advertisement

Coronavirus tracker: How many COVID-19 cases are there in Canada and worldwide? The latest maps and charts

Canada vaccine tracker: How many COVID-19 doses have been administered so far?

COVID-19 news: Updates and essential resources about the pandemic

The donation by the Mastercard Foundation over the next three years is aimed at acquiring vaccines for 50 million people in Africa, boosting the delivery of millions of additional vaccines by improving distribution and reducing vaccine hesitancy, training workers for a planned vaccine manufacturing sector in Africa, and strengthening the Africa Centres for Disease Control and Prevention.

The foundation, set up in Toronto in 2006 when Mastercard went public on the New York Stock Exchange, has increasingly focused on African programs in recent years, setting up offices across Africa, spending more than US$4-billion on Africa programs and relocating its president to Rwanda.

The main vaccine program for lower-income countries, the non-profit COVAX initiative, has relied heavily on AstraZeneca doses from a factory in India – but the factory says it must focus on deliveries to India for the rest of this year, creating a projected shortfall of 190 million doses by the end of this month. A dozen higher-income countries are trying to ease the shortage by sharing doses with COVAX, but Canada has made no decision on dose-sharing so far.

The COVAX problems are just the latest challenge for Africa, where supply shortages have jeopardized the African Union’s goal of vaccinating 60 per cent of the continent’s 1.3 billion people by the end of next year. And many African countries are now facing a third wave of the pandemic, with a surge of new cases and deaths in recent days.

“Addressing this inequity is a moral imperative,” said Reeta Roy, president and chief executive of the Mastercard Foundation, as she announced the donation at an online event with African leaders on Tuesday.

“Ensuring equitable access and delivery of vaccines across Africa is urgent,” she said.

John Nkengasong, director of the Africa Centres for Disease Control and Prevention, said the foundation’s donation is a “game changer” for the continent’s fight against the pandemic.

Story continues below advertisement

Rwandan President Paul Kagame said the donation was “practical and immediate” and will save lives.

South African Health Minister Zweli Mkhize called the announcement “a vital shot in the arm” for Africa. While many Western pharmaceutical companies have conducted trials of their vaccines in African countries, the continent is still “last in the queue” for COVID-19 vaccines, he said.

“This is unjust and contrary to human rights,” Mr. Mkhize said. “This is an unsustainable situation.”

Despite the Mastercard Foundation’s donation, Africa still faces huge challenges in obtaining vaccines. In addition to the COVAX shortfall, the African Union also faces delays in its own procurement plan. It has ordered 220 million vaccines from Johnson & Johnson, but the delivery has been stalled by the shutdown of a U.S. factory since April.

The factory in Baltimore, which had accidentally contaminated millions of vaccine doses, supplies ingredients for other Johnson & Johnson factories worldwide – including one in South Africa. Deliveries cannot resume until U.S. inspectors have given their full approval.

Dr. Nkengasong said he is hoping for the approval to be given this week. But even then, the first deliveries to Africa are unlikely to begin until August, he said. Some of the 220 million doses will not be delivered until next year.

Story continues below advertisement

Health advocates said the Mastercard Foundation’s donation is welcome, but insufficient. They are calling for a temporary waiver of vaccine patents to allow a massive increase in global production.

“Philanthropy cannot be a substitute for vaccine equity,” said Fatima Hassan, a South African activist and member of the People’s Vaccine Alliance campaign.

“We need billions of vaccines, not millions,” she told The Globe and Mail. “We need more manufacturing licensing and capacity. Governments need to prioritize and invest for future production. We are getting 99 per cent of our vaccines from outside Africa.”


Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies